ScinoPharm, an active pharmaceutical ingredient (API) specialist, has been granted US7435818 which covers a crystalline form of Irinotecan hydrochloride having a powder X-ray diffraction pattern with peaks at 20.3956.+-.0.2, 22.2950.+-.0.2, 12.0744.+-.0.2, 8.4800.+-.0.2, and 11.8306.+-.0.2 degrees in two theta. The said patent covers crystalline form I, II, III and IV of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin monohydrochloride trihydrate (irinotecan hydrochloride).
Details are Here
No comments:
Post a Comment